Cellectis presents AMELI-01 trial results and CAR T-cell generation techniques at ASGCT meeting
Biotechnology company Cellectis will present results from its AMELI-01 clinical trial and new techniques for CAR T-cell generation at the ASGCT annual meeting. Presentations focus on utilizing gene editing for cell therapies.
Biotechnology company Cellectis is participating in the American Society of Gene and Cell Therapy (ASGCT) annual meeting to present research findings from its AMELI-01 clinical program and new methods for CAR T-cell generation.
The company's oral presentation will cover the AMELI-01 study, which focuses on an allogeneic CAR T-cell therapy developed by Cellectis for the treatment of hematologic malignancies. The presentation will provide insights into the clinical progression of this therapeutic approach.
Additionally, Cellectis will present a poster detailing techniques for enhancing the generation of CAR T-cells using the company's Multiplex engineering technology. This technology aims to improve and refine T-cell characteristics, potentially leading to increased treatment efficacy and safety.
The ASGCT annual meeting is a significant event in the gene and cell therapy field, and Cellectis' participation highlights the company's contributions to advancements in these areas. The presentations offer industry professionals a deeper understanding of the company's research and development in gene editing and cell therapy.